Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update

World Journal of Gastroenterology

Volumn 21, Issue 22, 2015, Pages 6820-6834

  Athyros, Vasilios G ^a   Tziomalos, Konstantinos ^b   Katsiki, Niki ^a   Doumas, Michael ^a   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^c  

^a Aristotle University and Hippokration General Hospital   (Greece)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Arterial stiffness; Cardiovascular disease; Chronic kidney disease; Inflammation; Liver fibrosis; Non alcoholic fatty liver disease; Nonalcoholic steatohepatitis; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ALANINE AMINOTRANSFERASE; ATORVASTATIN; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PITAVASTATIN; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DETERIORATION; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; HUMAN; HYPOLIPEMIA; LIVER FIBROSIS; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DYSLIPIDEMIA; ECHOGRAPHY; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER FUNCTION; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PRIMARY PREVENTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; TREATMENT DURATION; BIOPSY; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMORBIDITY; DIABETES MELLITUS, TYPE 2; LIFESTYLE; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; RISK REDUCTION;

BIOPSY; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMORBIDITY; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 84930860402     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i22.6820     Document Type: Article

References (131)

1. Baran B, Akyüz F. Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning? World J Gastroenterol 2014; 20: 14219-14229 [PMID: 25339808 DOI: 10.3748/wjg.v20. i39.14219]
2. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x]
3. Jiang CM, Pu CW, Hou YH, Chen Z, Alanazy M, Hebbard L. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. World J Gastroenterol 2014; 20: 16464-16473 [PMID: 25469014 DOI: 10.3748/wjg.v20.i44.16464]
4. Eguchi A, Povero D, Alkhouri N, Feldstein AE. Novel therapeutic targets for nonalcoholic fatty liver disease. Expert Opin Ther Targets 2013; 17: 773-779 [PMID: 23600493 DOI: 10.1517/14728 222.2013.789502]
5. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45: 600-606 [PMID: 16899321]
6. Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J Gastroenterol 2014; 20: 13306-13324 [PMID: 25309067 DOI: 10.3748/wjg.v20. i37.13306]
7. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357-1365 [PMID: 23175136 DOI: 10.1002/hep.26156]
8. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2011; 33: 525-540 [PMID: 21198708 DOI: 10.1111/j.1365-2036.2010.04556. x]
9. Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci 2013; 14: 20704-20728 [PMID: 24132155 DOI: 10.3390/ijms141020704]
10. Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver 2012; 6: 149-171 [PMID: 22570745 DOI: 10.5009/gnl.2012.6.2.149]
11. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sørensen TI, Becker U, Bendtsen F. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750-755 [PMID: 15082596 DOI: 10.1136/ gut.2003.019984]
12. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873 [PMID: 17006923 DOI: 10.1002/hep.21327]
13. Söderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602 [PMID: 20014114 DOI: 10.1002/hep.23314]
14. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002; 50: 585-588 [PMID: 11950797]
15. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998; 29: 495-501 [PMID: 9765002]
16. Haflidadottir S, Jonasson JG, Norland H, Einarsdottir SO, Kleiner DE, Lund SH, Björnsson ES. Long-term follow-up and liverrelated death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol 2014; 14: 166 [PMID: 25260964 DOI: 10.1186/1471-230X-14-166]
17. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321 [PMID: 15915461 DOI: 10.1002/ hep.20701]
18. Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, Haflidadottir S, Day CP, George J. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 782-9.e4 [PMID: 23860502 DOI: 10.1053/j.gastro.2013.06.057]
19. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854 [PMID: 17393509 DOI: 10.1002/hep.21496]
20. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ; Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104-1112 [PMID: 19523535 DOI: 10.1016/j.cgh.2009.05.033]
21. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander- Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-1447 [PMID: 18390575 DOI: 10.1136/ gut.2007.146019]
22. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649 [PMID: 21039302 DOI: 10.3109/0785 3890.2010.518623]
23. Liu H, Lu HY. Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol 2014; 20: 8407-8415 [PMID: 25024598 DOI: 10.3748/wjg.v20.i26.8407]
24. Luo J, Xu L, Li J, Zhao S. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease. Eur J Gastroenterol Hepatol 2015; 27: 193-199 [PMID: 25563143 DOI: 10.1097/ MEG.0000000000000254]
25. Takahashi Y, Kurosaki M, Tamaki N, Yasui Y, Hosokawa T, Tsuchiya K, Nakanishi H, Itakura J, Izumi N. Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications. Hepatol Res 2014; Epub ahead of print [PMID: 25145976 DOI: 10.1111/hepr.12405]
26. Athyros VG, Elisaf MS, Alexandrides T, Achimastos A, Ganotakis E, Bilianou E, Karagiannis A, Liberopoulos EN, Tziomalos K, Mikhailidis DP; Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative Group. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology 2012; 63: 358-366 [PMID: 22007026 DOI: 10.1177/0003319711421341]
27. Doycheva I, Patel N, Peterson M, Loomba R. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. J Diabetes Complications 2013; 27: 293-300 [PMID: 23312215 DOI: 10.1016/j.jdiacomp.2012.10.008]
28. Athyros VG, Hatzitolios A, Karagiannis A, Didangelos TP, Iliadis F, Dolgyras S, Vosnakidis T, Vasiliadis P, Malias I, Tziomalos K, Samouilidou M, Mikhailidis DP; INDEED Collaborative Grou. Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study. Curr Med Res Opin 2009; 25: 1931-1940 [PMID: 19558210 DOI: 10.1185/030079909 03073035]
29. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. The role of statins in the treatment of type 2 diabetes mellitus: an update. Curr Pharm Des 2014; 20: 3665-3674 [PMID: 24040875 DOI: 10.2174/13816128113196660673]
30. Tziomalos K, Athyros VG, Karagiannis A. Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. Curr Vasc Pharmacol 2012; 10: 162-172 [PMID: 22239625 DOI: 10.2174/157016112799305012]
31. Duvnjak M, Lerotić I, Barsić N, Tomasić V, Virović Jukić L, Velagić V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 2007; 13: 4539-4550 [PMID: 17729403 DOI: 10.3748/wjg.v13.i34.4539]
32. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014; 5: 211-218 [PMID: 25018867 DOI: 10.1136/ flgastro-2013-100403]
33. Athyros VG, Katsiki N, Karagiannis A. Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease. Expert Opin Ther Targets 2013; 17: 861-862 [PMID: 23763554 DOI: 10.1517/14728222.2013.811024]
34. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147 [PMID: 12859163 DOI: 10.7326/0003-4819-139-2-200307150-00013]
35. Locatelli F, Pozzoni P, Tentori F, del Vecchio L. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant 2003; 18 Suppl 7: vii2-vii9 [PMID: 12953023 DOI: 10.1093/ndt/gfg1072]
36. Iseki K. Chronic kidney disease in Japan. Intern Med 2008; 47: 681-689 [PMID: 18421182 DOI: 10.2169/internalmedicine.47.0906]
37. Orlić L, Mikolasevic I, Bagic Z, Racki S, Stimac D, Milic S. Chronic kidney disease and nonalcoholic Fatty liver disease-is there a link? Gastroenterol Res Pract 2014; 2014: 847539 [PMID: 24729784 DOI: 10.1155/2014/847539]
38. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N; European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056 [PMID: 15814534 DOI: 10.1093/ndt/gfh813]
39. Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J Hepatol 2011; 54: 1020-1029 [PMID: 21145850 DOI: 10.1016/j.jhep.2010.11.007]
40. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, Muggeo M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabeticpatients. Diabetologia 2008; 51: 444-450 [PMID: 18058083 DOI: 10.1007/s00125-007-0897-4]
41. Hwang ST, Cho YK, Yun JW, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI, Rhee EJ, Oh KW, Lee WY, Jin W. Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Intern Med J 2010; 40: 437-442 [PMID: 19460054 DOI: 10.1111/j.1445-5994.2009.01979.x]
42. Targher G, Kendrick J, Smits G, Chonchol M. Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Nutr Metab Cardiovasc Dis 2010; 20: 583-590 [PMID: 19699624 DOI: 10.1016/j.numecd.2009.05.012]
43. Targher G, Bosworth C, Kendrick J, Smits G, Lippi G, Chonchol M. Relationship of serum bilirubin concentrations to kidney function and albuminuria in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Clin Chem Lab Med 2009; 47: 1055-1062 [PMID: 19634983 DOI: 10.1515/CCLM.2009.244]
44. Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014; 59: 1174-1197 [PMID: 24002776 DOI: 10.1002/hep.26717]
45. Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagström H, Yoon SK, Charatcharoenwitthaya P, George J, Barrera F, Haflidadóttir S, Björnsson ES, Armstrong MJ, Hopkins LJ, Gao X, Francque S, Verrijken A, Yilmaz Y, Lindor KD, Charlton M, Haring R, Lerch MM, Rettig R, Völzke H, Ryu S, Li G, Wong LL, Machado M, Cortez-Pinto H, Yasui K, Cassader M. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014; 11: e1001680 [PMID: 25050550 DOI: 10.1371/journal.pmed.1001680]
46. Dogru T, Genc H, Tapan S, Aslan F, Ercin CN, Ors F, Kara M, Sertoglu E, Karslioglu Y, Bagci S, Kurt I, Sonmez A. Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2013; 78: 712-717 [PMID: 22676641 DOI: 10.1111/j.1365-2265.2012.04460.x]
47. Jin K, Norris K, Vaziri ND. Dysregulation of hepatic fatty acid metabolism in chronic kidney disease. Nephrol Dial Transplant 2013; 28: 313-320 [PMID: 23045433 DOI: 10.1093/ndt/gfs350]
48. Allen AM, Kim WR, Therneau TM, Larson JJ, Heimbach JK, Rule AD. Chronic kidney disease and associated mortality after liver transplantation-a time-dependent analysis using measured glomerular filtration rate. J Hepatol 2014; 61: 286-292 [PMID: 24713190 DOI: 10.1016/j.jhep.2014.03.034]
49. Musso G, Tabibian JH, Charlton M. Chronic kidney disease (CKD) and NAFLD: time for awareness and screening. J Hepatol 2015; 62: 983-984 [PMID: 25529627 DOI: 10.1016/j.jhep.2014.11.044]
50. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305 [PMID: 15385656 DOI: 10.1056/NEJMoa041031]
51. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-495 [PMID: 15590763 DOI: 10.1681/ASN.2004030203]
52. Lai YC, Cheng BC, Hwang JC, Lee YT, Chiu CH, Kuo LC, Chen JB. Association of fatty liver disease with nonfatal cardiovascular events in patients undergoing maintenance hemodialysis. Nephron Clin Pract 2013; 124: 218-223 [PMID: 24503573 DOI: 10.1159/000357952]
53. Targher G, Byrne CD. Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 2013; 98: 483-495 [PMID: 23293330 DOI: 10.1210/jc.2012-3093]
54. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Statins and nonalcoholic fatty liver disease: a bright future? Expert Opin Investig Drugs 2013; 22: 1089-1093 [PMID: 23889731 DOI: 10.1517/13543784.2013.824423]
55. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Are statins 'IDEAL' for non-alcoholic fatty liver disease? Curr Med Res Opin 2014; 30: 229-231 [PMID: 24127654 DOI: 10.1185/03007995.201 3.855192]
56. Kostapanos MS, Athyros VG, Karagiannis A, Mikhailidis DP. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci 2012; 57: 1109 [PMID: 22311368 DOI: 10.1007/s10620-012-2066-y]
57. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Elisaf M. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-734 [PMID: 15220366 DOI: 10.1136/jcp.2003.012989]
58. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220-228 [PMID: 12201623 DOI: 10.1185/030 079902125000787]
59. Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP; GREACE Study Collaborative Group. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003; 19: 615-617 [PMID: 14606984 DOI: 10.1185/030079903125002315]
60. Zoppini G, Fedeli U, Gennaro N, Saugo M, Targher G, Bonora E. Mortality from chronic liver diseases in diabetes. Am J Gastroenterol 2014; 109: 1020-1025 [PMID: 24890439 DOI: 10.1038/ajg.2014.132]
61. Athyros VG, Papageorgiou AA, Symeonidis AN, Didangelos TP, Pehlivanidis AN, Bouloukos VI, Mikhailidis DP; GREACE Study Collaborative Group. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology 2003; 54: 679-690 [PMID: 14666956 DOI: 10.1177/000331970305400607]
62. Lonardo A, Ballestri S, Targher G, Loria P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2015; 9: 629-650 [PMID: 25327387 DOI: 10.1586/17474124.2015.965143]
63. Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis 2014; 64: 638-652 [PMID: 25085644 DOI: 10.1053/j.ajkd.2014.05.019]
64. Athyros VG, Mikhailidis DP. Uric acid, chronic kidney disease and type 2 diabetes: a cluster of vascular risk factors. J Diabetes Complications 2014; 28: 122-123 [PMID: 24388550 DOI: 10.1016/j.jdiacomp.2013.11.012]
65. Katsiki N, Karagiannis A, Athyros VG, Mikhailidis DP. Hyperuricaemia: more than just a cause of gout? J Cardiovasc Med (Hagerstown) 2013; 14: 397-402 [PMID: 23032963 DOI: 10.2459/ JCM.0b013e3283595adc]
66. Athyros VG, Karagiannis A, Ganotakis ES, Paletas K, Nicolaou V, Bacharoudis G, Tziomalos K, Alexandrides T, Liberopoulos EN, Mikhailidis DP; Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011; 27: 1659-1668 [PMID: 21714711 DOI: 10.1185/03007995.2011.59578 2]
67. Cardoso AS, Gonzaga NC, Medeiros CC, Carvalho DF. Association of uric acid levels with components of metabolic syndrome and non-alcoholic fatty liver disease in overweight or obese children and adolescents. J Pediatr (Rio J) 2013; 89: 412-418 [PMID: 23791233 DOI: 10.1016/j.jped.2012.12.008]
68. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: anactive component or an innocent bystander? Metabolism 2006; 55: 1293-1301 [PMID: 16979398]
69. Katsiki N, Doumas M, Athyros VG, Karagiannis A. Hyperuricemia as a risk factor for cardiovascular disease. Expert Rev Cardiovasc Ther 2015; 13: 19-20 [PMID: 25428565 DOI: 10.1586/14779072. 2015.987129]
70. Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, Tziomalos K, Ganotakis ES, Elisaf M. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: 118-127 [PMID: 16998214 DOI: 10.1093/ndt/gfl538]
71. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis D. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 66: 1714-1715 [PMID: 15458477 DOI: 10.1111/j.1523-1755.2004.938-8.x]
72. Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Milionis HJ, Mikhailidis DP; GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004; 43: 589-599 [PMID: 15042535 DOI: 10.1053/j.ajkd.2003.12.023]
73. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 2005; 11: 4161-4175 [PMID: 16375738 DOI: 10.2174/13816120577491330 9]
74. Li N, Zhang GW, Zhang JR, Jin D, Li Y, Liu T, Wang RT. Nonalcoholic fatty liver disease is associated with progression of arterial stiffness. Nutr Metab Cardiovasc Dis 2015; 25: 218-223 [PMID: 25456154 DOI: 10.1016/j.numecd.2014.10.002]
75. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318-1327 [PMID: 20338492 DOI: 10.1016/j.jacc.2009.10.061]
76. Lee YJ, Shim JY, Moon BS, Shin YH, Jung DH, Lee JH, Lee HR. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci 2012; 57: 196-203 [PMID: 21750929 DOI: 10.1007/s10620-011-1819-3]
77. Yu XY, Zhao Y, Song XX, Song ZY. Association between nonalcoholic fatty liver disease and arterial stiffness in the nonobese, non-hypertensive, and non-diabetic young and middleaged Chinese population. J Zhejiang Univ Sci B 2014; 15: 879-887 [PMID: 25294377 DOI: 10.1631/jzus.B1400028]
78. Sunbul M, Agirbasli M, Durmus E, Kivrak T, Akin H, Aydin Y, Ergelen R, Yilmaz Y. Arterial stiffness in patients with nonalcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis 2014; 237: 490-493 [PMID: 25463079 DOI: 10.1016/j.atherosclerosis.2014.10.004]
79. Wang MC, Tsai WC, Chen JY, Huang JJ. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 2005; 45: 494-501 [PMID: 15754271 DOI: 10.1053/j.ajkd.2004.11.011]
80. Haydar AA, Covic A, Colhoun H, Rubens M, Goldsmith DJ. Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int 2004; 65: 1790-1794 [PMID: 15086918 DOI: 10.1111/j.1523-1755.2004.00581.x]
81. Chen JY, Chou CH, Tsai WC, Wang MC, Ho CS, Li YH, Tsai YS, Tsai LM. Effects of increased systemic inflammation and central obesity on arterial stiffness in patients with nonalcoholic fatty liver disease. J Am Soc Hypertens 2012; 6: 253-260 [PMID: 22651911 DOI: 10.1016/j.jash.2012.04.003]
82. Yu KJ, Zhang MJ, Li Y, Wang RT. Increased whole blood viscosity associated with arterial stiffness in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2014; 29: 540-544 [PMID: 23981121 DOI: 10.1111/jgh.12368]
83. Li Y, Tian XX, Liu T, Wang RT. Association between whole blood viscosity and arterial stiffness in patients with type 2 diabetes mellitus. Endocrine 2015; 49: 148-154 [PMID: 25312690 DOI: 10.1007/s12020-014-451-03]
84. Cecelja M, Chowienczyk P. Role of arterial stiffness in cardiovascular disease. JRSM Cardiovasc Dis 2012; 1: [PMID: 24175067 DOI: 10.1258/cvd.2012.012016]
85. London GM. Mechanisms of arterial calcifications and consequences for cardiovascular function. Kidney Int Suppl (2011) 2013; 3: 442-445 [PMID: 25019027 DOI: 10.1038/kisup.2013.92]
86. Liu B, Che W, Yan H, Zhu W, Wang H. Effects of rosuvastatin vs. simvastatin/ezetimibe on arterial wall stiffness in patients with coronary artery disease. Intern Med 2013; 52: 2715-2719 [PMID: 24334573 DOI: 10.2169/internalmedicine.52.0731]
87. Georgianos PI, Sarafidis PA, Lasaridis AN. Arterial stiffness: a novel cardiovascular risk factor in kidney disease patients. Curr Vasc Pharmacol 2015; 13: 229-238 [PMID: 24007427]
88. Dahlén EM, Bjarnegard N, Länne T, Nystrom FH, Ostgren CJ. Sagittal abdominal diameter is a more independent measure compared with waist circumference to predict arterial stiffness in subjects with type 2 diabetes-a prospective observational cohort study. Cardiovasc Diabetol 2013; 12: 55 [PMID: 23536999 DOI: 10.1186/1475-2840-12-55]
89. Katsiki N, Koumaras C, Athyros VG, Karagiannis A. Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk. Angiology 2012; 63: 9-11 [PMID: 22144689 DOI: 10.1177/0003319711406256]
90. Tziomalos K, Athyros VG, Karagiannis A. Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome. Curr Pharm Des 2014; Epub ahead of print [PMID: 24745924]
91. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Metabolic syndrome and non-cardiac vascular diseases: an update from human studies. Curr Pharm Des 2014; 20: 4944-4952 [PMID: 24320038 DOI: 10.2174/1381612819666131206100750]
92. Chen TH, Liao FT, Yang YC, Wang JJ. Inhibition of inducible nitric oxide synthesis ameliorates liver ischemia and reperfusion injury induced transient increase in arterial stiffness. Transplant Proc 2014; 46: 1112-1116 [PMID: 24815141 DOI: 10.1016/j.trans proceed.2014.01.002]
93. Athyros VG, Pagourelias ED, Gossios TD, Vasilikos VG. Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we kill Two Birds with One Stone? Curr Vasc Pharmacol 2014; Epub ahead of print [PMID: 25426732]
94. Kanaki AI, Sarafidis PA, Georgianos PI, Kanavos K, Tziolas IM, Zebekakis PE, Lasaridis AN. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens 2013; 26: 608-616 [PMID: 23449607 DOI: 10.1093/ajh/ hps098]
95. Tousoulis D, Oikonomou E, Siasos G, Chrysohoou C, Zaromitidou M, Kioufis S, Maniatis K, Dilaveris P, Miliou A, Michalea S, Papavassiliou AG, Stefanadis C. Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. Atherosclerosis 2013; 227: 367-372 [PMID: 23433403 DOI: 10.1016/j.atherosclerosis.2013.01.015]
96. Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Sharman JE, Coombes JS. Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial. J Atheroscler Thromb 2010; 17: 235-241 [PMID: 20032570 DOI: 10.5551/jat.2683]
97. Papademetriou V, Katsiki N, Doumas M, Faselis C. Halting arterial aging in patients with cardiovascular disease: hypolipidemic and antihypertensive therapy. Curr Pharm Des 2014; 20: 6339-6349 [PMID: 24953392 DOI: 10.2174/13816128206661406 20162157]
98. Koumaras C, Katsiki N, Athyros VG, Karagiannis A. Metabolic syndrome and arterial stiffness: the past, the present and the future. J Cardiovasc Med (Hagerstown) 2013; 14: 687-689 [PMID: 24335882 DOI: 10.2459/JCM.0b013e3283657c96]
99. Koumaras C, Tziomalos K, Stavrinou E, Katsiki N, Athyros VG, Mikhailidis DP, Karagiannis A. Effects of renin-angiotensinaldosterone system inhibitors and beta-blockers on markers of arterial stiffness. J Am Soc Hypertens 2014; 8: 74-82 [PMID: 24139833 DOI: 10.1016/j.jash.2013.09.001]
100. Stojakovic T, Claudel T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Sourij H, Stauber RE, Winkler K, März W, Wascher TC, Trauner M. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis 2010; 209: 178-183 [PMID: 19782361 DOI: 10.1016/j.atherosclerosis.2009.08.052]
101. Mäki-Petäjä KM, Wilkinson IB. Anti-inflammatory drugs and statins for arterial stiffness reduction. Curr Pharm Des 2009; 15: 290-303 [PMID: 19149619 DOI: 10.2174/138161209787354221]
102. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-967 [PMID: 12809815 DOI: 10.1111/ j.1572-0241.2003.07486.x]
103. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530.e1; quiz e60 [PMID: 21440669 DOI: 10.1016/j.cgh.2011.03.020]
104. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126: 1287-1292 [PMID: 15131789 DOI: 10.1053/j.gastro.2004.02.015]
105. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005; 329: 62-65 [PMID: 15711421 DOI: 10.1097/00000441-200502000-00002]
106. Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, Davis BR, Friedman CP, Braunwald E. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 105: 2341-2346 [PMID: 12021218 DOI: 10.1161/01.CIR.0000017634.00171.24]
107. Gómez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006; 23: 1643-1647 [PMID: 16696815 DOI: 10.1111/j.1365-2036.2006.02926.x]
108. Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, Ishitobi T, Nonaka M, Chayama K. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57: 1711-1718 [PMID: 19013295 DOI: 10.1016/ j.metabol.2008.07.030]
109. Kimura Y, Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010; 45: 750-757 [PMID: 20112031 DOI: 10.1007/s00535-010-0203-y]
110. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol 2009; 43: 990-994 [PMID: 19448566 DOI: 10.1097/ MCG.0b013e31819c392e]
111. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, Pagourelias ED, Theocharidou E, Karagiannis A, Mikhailidis DP. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-1922 [PMID: 21109302 DOI: 10.1016/ S0140-6736(10)61272-X]
112. Hyogo H, Ikegami T, Tokushige K, Hashimoto E, Inui K, Matsuzaki Y, Tokumo H, Hino F, Tazuma S. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res 2011; 41: 1057-1065 [PMID: 21951922 DOI: 10.1111/j.1872-034X.2011.00849.x]
113. Hyogo H, Yamagishi S, Maeda S, Kimura Y, Ishitobi T, Chayama K. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property. Dig Liver Dis 2012; 44: 492-496 [PMID: 22265683 DOI: 10.1016/j.dld.2011.12.013]
114. Nakahara T, Hyogo H, Kimura Y, Ishitobi T, Arihiro K, Aikata H, Takahashi S, Chayama K. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res 2012; 42: 1065-1072 [PMID: 22583925 DOI: 10.1111/j.1872-034X.2012.01034.x]
115. Athyros VG, Giouleme O, Ganotakis ES, Elisaf M, Tziomalos K, Vassiliadis T, Liberopoulos EN, Theocharidou E, Karagiannis A, Mikhailidis DP. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011; 7: 796-805 [PMID: 22291824 DOI: 10.5114/aoms.2011.25554]
116. Tikkanen MJ, Fayyad R, Faergeman O, Olsson AG, Wun CC, Laskey R, Kastelein JJ, Holme I, Pedersen TR. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168: 3846-3852 [PMID: 24001698 DOI: 10.1016/ j.ijcard.2013.06.024]
117. Kargiotis K, Katsiki N, Athyros VG, Giouleme O, Patsiaoura K, Katsiki E, Mikhailidis DP, Karagiannis A. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report. Curr Vasc Pharmacol 2014; 12: 505-511 [PMID: 24805248 DOI: 10.2174/15 701611113119990009]
118. Bader T. Yes! Statins can be given to liver patients. J Hepatol 2012; 56: 305-307 [PMID: 21963520 DOI: 10.1016/ j.jhep.2011.08.016]
119. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23: 2009-2026 [PMID: 17659159 DOI: 10.1185/030079907 X210507]
120. Enjoji M, Machida K, Kohjima M, Kato M, Kotoh K, Matsunaga K, Nakashima M, Nakamuta M. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids Health Dis 2010; 9: 29 [PMID: 20222991 DOI: 10.1186/1476-511X-9-29]
121. Yoneda M, Fujita K, Nozaki Y, Endo H, Takahashi H, Hosono K, Suzuki K, Mawatari H, Kirikoshi H, Inamori M, Saito S, Iwasaki T, Terauchi Y, Kubota K, Maeyama S, Nakajima A. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. Hepatol Res 2010; 40: 566-573 [PMID: 20412324 DOI: 10.1111/j.1872-034X.2010.00644.x]
122. Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, Itoh Y, Yoshikawa T, Fukui M, Hasegawa G, Nakamura N, Ohta M, Obayashi H, Okanoue T. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-107 [PMID: 20658156 DOI: 10.1007/ s00535-010-0291-8]
123. Takeshita Y, Takamura T, Honda M, Kita Y, Zen Y, Kato K, Misu H, Ota T, Nakamura M, Yamada K, Sunagozaka H, Arai K, Yamashita T, Mizukoshi E, Kaneko S. The effects of ezetimibe on nonalcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 2014; 57: 878-890 [PMID: 24407920 DOI: 10.1007/s00125-013-3149-9]
124. Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008; 14: 6395-6400 [PMID: 19009658]
125. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 56: 944-951 [PMID: 22023985 DOI: 10.1016/j.jhep.2011.08.018]
126. Subasi CF, Aykut UE, Yilmaz Y. Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2015; 27: 137-141 [PMID: 25486027 DOI: 10.1097/MEG.0000000000000255]
127. Karbasi-Afshar R, Saburi A, Khedmat H. Cardiovascular disorders in the context of non-alcoholic Fatty liver disease: a literature review. J Tehran Heart Cent 2014; 9: 1-8 [PMID: 25561963]
128. Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol 2014; 34: 1155-1161 [PMID: 24743428 DOI: 10.1161/ATVBAHA.114.303034]
129. Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 1724-1745 [PMID: 24587651 DOI: 10.3748/wjg.v20.i7.1724]
130. Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681 [PMID: 21067804 DOI: 10.1016/ S0140-6736(10)61350-5]
131. Cholesterol Treatment Trialists' (CTT) Collaborators; Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590 [PMID: 22607822 DOI: 10.1016/S0140-6736(12)60367-5]